Table 1 Patient demographics and magnetic resonance imaging findings (n = 251)
Group A (n = 162) | Group B (N = 89) | p-value | |
|---|---|---|---|
Median (IQR) age, years | 67 (61–72) | 68 (60–71) | 0.846 |
Median (IQR) PSA. ng/ml | 8.10 (6.05–14.00) | 8.59 (5.65–12.32) | 0.997 |
Median IQR) f/t PSA-ratio,% | 12 (9–17) | 13 (9–19) | 0.309 |
Median (IQR) prostate volume, ml | 48 (35–60) | 50 (37–70) | 0.087 |
Suspicous DRE, n (%) | 23 (14%) | 26 (29%) | 0.007 |
No. of prior biopsies, n (%) | |||
Primary biopsy | 53 (33%) | 41 (46%) | 0.041 |
1 | 59 (36%) | 28 (32%) | 0.489 |
2 | 33 (20%) | 13 (15%) | 0.308 |
≥3 | 17 (10%) | 7 (8%) | 0.655 |
Localization of lesions with maximum PI-RADS on mpMRI, n (%) | |||
Apex | 72 (44%) | 35 (39%) | 0.505 |
Midgland | 43 (27%) | 32 (36%) | 0.149 |
Base | 47 (29%) | 22 (25%) | 0.555 |
Anterior | 45 (28%) | 28 (32%) | 0.563 |
Median (IQR) no. of lesions per patient | 1 (1–2) | 1 (1–2) | 0.451 |
Maximum diameter of lesions (mm) | 14 (10–17) | 13 (10–18) | 0.885 |
Mean (SD) of cores taken per patient | 13.7 (±1.6) | 13.2 (±1.2) | 0.009 |
Mean (SD) TBs per patient | 3.8 (±1.5) | 3.4 (±0.9) | 0.031 |
Maximum mpMRI Score, n (%)a | |||
PI-RADS 3 | 31 (19%) | 8 (9%) | 0.044 |
PI-RADS 4 | 83 (51%) | 43 (48%) | 0.693 |
PI-RADS 5 | 48 (30%) | 38 (43%) | 0.051 |